Cullinan Therapeutics 将来の成長

Future 基準チェック /26

Cullinan Therapeuticsの収益は年間1%で減少すると予測されていますが、年間収益は年間46.1%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-27.2% 10.2%なると予測されています。

主要情報

-1.0%

収益成長率

10.22%

EPS成長率

Biotechs 収益成長	23.0%
収益成長率	46.1%
将来の株主資本利益率	-27.18%
アナリストカバレッジ	Good
最終更新日	17 Dec 2025

今後の成長に関する最新情報

Recent updates

Cullinan Therapeutics: Worthy Of A Small Position

Oct 17

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Oct 10

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Jun 21

Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data

Apr 08

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Feb 27

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Jan 08

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Nov 20

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Aug 30

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

業績と収益の成長予測

NasdaqGS:CGEM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	21	-256	-211	-210	4
12/31/2027	41	-192	-201	-200	7
12/31/2026	25	-192	-191	-190	10
12/31/2025	7	-214	-177	-176	9
9/30/2025	N/A	-217	-174	-174	N/A
6/30/2025	N/A	-207	-172	-172	N/A
3/31/2025	N/A	-179	-150	-150	N/A
12/31/2024	N/A	-167	-145	-145	N/A
9/30/2024	N/A	-144	-127	-127	N/A
6/30/2024	N/A	-142	-127	-127	N/A
3/31/2024	N/A	-132	-122	-122	N/A
12/31/2023	N/A	-153	-134	-134	N/A
9/30/2023	N/A	-156	-142	-141	N/A
6/30/2023	N/A	-142	-163	-161	N/A
3/31/2023	N/A	65	-157	-156	N/A
12/31/2022	N/A	111	-128	-127	N/A
9/30/2022	N/A	105	-117	-117	N/A
6/30/2022	N/A	113	-73	-73	N/A
3/31/2022	N/A	-78	-64	-64	N/A
12/31/2021	19	-66	-43	-43	N/A
9/30/2021	19	-61	-38	-38	N/A
6/30/2021	19	-54	-36	-36	N/A
3/31/2021	19	-47	-26	-26	N/A
12/31/2020	N/A	-52	-30	-30	N/A
9/30/2020	N/A	-28	-25	-25	N/A
6/30/2020	N/A	-25	-22	-22	N/A
3/31/2020	N/A	-21	-21	-21	N/A
12/31/2019	N/A	-21	-21	-21	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CGEM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CGEM今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CGEM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CGEMの収益 ( 46.1% ) US市場 ( 10.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: CGEMの収益 ( 46.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CGEM 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/01/02 14:02
終値	2026/01/02 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cullinan Therapeutics, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。16

アナリスト	機関
Julian Harrison	BTIG
Thomas Shrader	BTIG
Kaveri Pohlman	BTIG

Cullinan Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 11% to US$28.78

Price target decreased by 12% to US$28.25

Consensus revenue estimates fall by 52%

Consensus EPS estimates upgraded to US$3.01 loss

Consensus revenue estimates increase by 19%

Price target increased by 13% to US$28.71

Recent updates

President recently sold US$99k worth of stock

Price target increased by 11% to US$28.78

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash Meeting

Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Cullinan Therapeutics, Inc. to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Cullinan Therapeutics, Inc. Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Cullinan Therapeutics: Worthy Of A Small Position

Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Cullinan Therapeutics, Inc. Announces Board Changes, Effective August 7, 2025

Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell 3000E Growth Index

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

Price target decreased by 12% to US$28.25

Cullinan Therapeutics, Inc. to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjogren's Disease in the United States

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

Cullinan Therapeutics, Inc. to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Cullinan Therapeutics, Inc. Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978

Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data

Consensus revenue estimates fall by 52%

President recently sold US$107k worth of stock

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

New major risk - Shareholder dilution

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

President recently sold US$100k worth of stock

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024

Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Chief Scientific Officer notifies of intention to sell stock

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors